Pfizer’s JAK/TEC inhibitor Litfulo has been recommended for NHS use as a treatment for hair loss caused by severe alopecia areata, the first drug therapy for a condition that affects around ...

Pfizer said that Litfulo (ritlecitinib) is the first alopecia areata therapy to be cleared for use in adolescents in the EU. JAK1/2 inhibitor Olumiant (baricitinib) was the first drug to be ...

Despite winning an alopecia areata approval for its drug Leqselvi in July ... competitor to Eli Lilly and Incyte’s Olumiant and Pfizer’s Litfulo. Sun, which had been plotting a mid-October ...

The daily pill has been approved by drug body ... manufacturer Pfizer. Helen Knight, director of medicines evaluation at NICE, said: "Our committee heard how severe alopecia areata can have ...

Kristen Whitney, DO, FAAD, dermatologist at Allegheny Health Network, explored the intricate management of alopecia areata, ...

Treatment with ritlecitinib sustained hair regrowth through week 48 in patients with alopecia areata (AA), and up to ... This study was funded by Pfizer. Piliang disclosed being a consultant ...

JAK inhibitors like baricitinib, ritlecitinib, and brepocitinib show promise in treating alopecia areata, with baricitinib ...

Earlier this year, a new drug was recommended on the NHS in England and Wales for the first time for patients aged 12 and over with severe alopecia areata. Alopecia is caused by the immune system ...

DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...